Skip to main content

sodium zirconium cyclosilicate

Generic: SODIUM ZIRCONIUM CYCLOSILICATE·Brand: LOKELMA, Lokelma

sodium zirconium cyclosilicate: sourced relationships with 1 company · 1 FDA decision.

sodium zirconium cyclosilicate evidence translation

What we can confirm

What it means

Source-backed records connect sodium zirconium cyclosilicate to AZN; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could sodium zirconium cyclosilicate → AZN affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Dated Pipeline Records (2)
CompanyDated record stage
ASTRAZENECA PLC (AZN)
Reported 2018-05-18 · Current development: unknownSource
Approved
ASTRAZENECA PLC (AZN)
Reported 2018-05-18 · Current development: unknownSource
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) and Clinical Studies (14) ] . LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. ( 1 ) Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 )(AZN)FDA ↗
NDA207078Type 1 - New Molecular EntityStandardOralFor Suspension

Frequently asked questions

Which companies have sourced relationships with sodium zirconium cyclosilicate?

sodium zirconium cyclosilicate has dated SEC/FDA relationship records for ASTRAZENECA PLC.

What is sodium zirconium cyclosilicate's latest FDA decision?

The most recent tracked FDA decision for sodium zirconium cyclosilicate is Approval for 1 INDICATIONS AND USAGE LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) and Clinical Studies (14) ] . LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. ( 1 ) Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 ), dated May 18, 2018.